secwatch.observer — SEC 8-K summary
======================================

Issuer:     Amneal Pharmaceuticals, Inc. (AMRX)
CIK:        0001723128
Form:       8-K
Filed at:   2022-11-04T23:59:59+00:00
Accession:  0001723128-22-000037
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Amneal Q3 2022 revenue $546M (+3.2% YoY), adj. EBITDA $126M, adj. EPS $0.14
---------------------------------------------------------------------------

- Net revenue $546M, up 3.2% from $529M in Q3 2021; GAAP net loss $3M (diluted EPS $(0.02)).
- Adjusted EBITDA $126M, down 5.1% YoY; adjusted diluted EPS $0.14 vs $0.21 in prior year.
- Full-year 2022 outlook maintained; management cites new product approvals and biosimilar launch momentum.
- AvKARE delivered double-digit growth; Generics and Specialty segments remained consistent.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1723128/000172312822000037/0001723128-22-000037-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1723128/000172312822000037/amrx-20221104.htm
  HTML page:      https://secwatch.observer/filing/0001723128-22-000037

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer